Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Department of Defence (DoD) has awarded a $1.53m contract to New Jersey Medical School-UMDNJ and an international consortium consisting of Euprotec and Fulhold to develop a new product that prevents multi-drug resistant skin infections and improves US soldiers recovery.
Subscribe to our email newsletter
Following funding from the DoD, the UK-based Euprotec is collaborating with Mauritius-based Fulhold and the New Jersey Medical School-UMDNJ to assess a topical broad spectrum antimicrobial agent for use in US soldiers’ battle-packs.
The Fulhold’s CHD-FA is considered to be suitable for use in soldiers’ battle-packs or in the first aid situations as it is safe and stable at high temperatures.
Euprotec CEO Dr Lloyd Payne said, "It is critical that we address antimicrobial resistance and CHD-FA offers significant potential for the prevention of serious wound infections."
CHD-FA also demonstrates potent broad spectrum antimicrobialactivity against a large range of multidrug resistant Gram positive and Gram negative bacteria such as MRSA, NDM-1 positive E. coli, carbapenem-resistant Enterobacteriaceae (CRE), tuberculosis and pathogenic fungi.
Fulhold director Wally Strickland said, "We have believed in the potential of CHD-FA to treat drug resistant wound infections for many years and have completed a number of research projects with Euprotec."